Saghir, N. S. E., Im, S., Azim, H. A., Eralp, Y., Yap, Y. S., Sandhu, M. S., Abdel-Razeq, H., Gupta, S., Artamonova, E., Rihani, J., Payan, J. C. M., Chattar, Y., Sopher, G. M., Gao, M., Lu, Y. (2025). First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1069